ClinicalTrials.gg
CompletedNCT01854918OSLER-2Updated Jun 11, 2019Results posted

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

A Phase 3 interventional study of Evolocumab and Standard of Care in Hyperlipidemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 363 sites in 25 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-11.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,681
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
Largest of 21
3,681 · median 307
Started
2013
with 6 others
Phase 3
12 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one has the largest enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 9th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.

03

Conditions studied

  • Hyperlipidemia and Mixed Dyslipidemia

Keywords

  • High cholesterol
  • Raised cholesterol
  • Cholesterol
  • Elevated Cholesterol
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Complete a qualifying evolocumab (AMG 145) parent study (ie, Study 20110114 [NCT01763827], 20110115 [NCT01763866], 20110116 [NCT01763905], 20110117 [NCT01763918], 20110109 [NCT01516879], 20120122 [NCT01953328], 20120332 [NCT01984424], 20120348 [NCT01849497], or 20120356 [NCT01879319]).

Exclusion criteria

Exclusion Criteria:

  • Experienced a treatment-related serious adverse event that led to study drug discontinuation in the parent study
  • Have an unstable medical condition, in the judgment of the investigator
  • Known sensitivity to any of the products to be administered during dosing
  • Currently enrolled in another device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,681 participants (actual)

Study arms

  • Active comparator
    Standard of Care

    Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product \[all-IP\] period.

    Biological: Evolocumab · Drug: Standard of Care

  • Experimental
    Evolocumab + Standard of Care

    Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.

    Biological: Evolocumab · Drug: Standard of Care

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen

    Also known as: AMG 145, Repatha

  • DrugStandard of Care

    Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.0, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.

    Time frame: 48 weeks in the SOC-controlled period and up to 2 years in the All-IP period

Secondary outcomes

  1. Percent Change From Baseline in LDL-C at Weeks 48 and 104

    Time frame: Baseline of the parent study and weeks 48 amd 104

  2. Change From Baseline in LDL-C at Weeks 48 and 104

    Time frame: Baseline of the parent study and weeks 48 amd 104

07

Results

Posted Jun 11, 2019

Participant flow

Participants were enrolled at 365 study centers in 24 countries in Europe, North America, and Asia Pacific from 23 April 2013 to 31 August 2015.

SOC-controlled Period (Year 1)
Participant flow — SOC-controlled Period (Year 1)
MilestoneStandard of CareEvolocumab + Standard of Care
Started12272454
Received evolocumab52452
Completed11972391
Not completed3063
Withdrew: Withdrawal by subject2049
Withdrew: Decision by sponsor21
Withdrew: Lost to follow-up38
Withdrew: Death55
All-IP Period (Years 2 and 3)
Participant flow — All-IP Period (Years 2 and 3)
MilestoneStandard of CareEvolocumab + Standard of Care
Started11972391
Received evolocumab11522291
Completed10792196
Not completed118195
Withdrew: Withdrawal by subject78117
Withdrew: Decision by sponsor811
Withdrew: Lost to follow-up2751
Withdrew: Death516

Outcome measures

PrimaryNumber of Participants With Adverse Events

Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.0, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.

Time frame:
48 weeks in the SOC-controlled period and up to 2 years in the All-IP period
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsYear 1: Standard of CareYear 1: Evolocumab + Standard of CareYears 2-3: SOC / Evolocumab + SOCYears 2-3: Evolocumab + SOC / Evolocumab + SOC
All adverse events79616559291789
Adverse events ≥ grade 251910707001339
Adverse events ≥ grade 3124225214379
Adverse events ≥ grade 47171135
Serious adverse events104195178332
AEs leading to discontinuation of evolocumab0552642
Fatal adverse events55316
Device related adverse events0572545
SecondaryPercent Change From Baseline in LDL-C at Weeks 48 and 104
Time frame:
Baseline of the parent study and weeks 48 amd 104
Reported as:
Mean · percent change
Percent Change From Baseline in LDL-C at Weeks 48 and 104
percent changeStandard of CareEvolocumab + Standard of Care
Week 487.43 ± 38.93-51.59 ± 28.88
Week 104-49.96 ± 33.29-50.31 ± 30.34
SecondaryChange From Baseline in LDL-C at Weeks 48 and 104
Time frame:
Baseline of the parent study and weeks 48 amd 104
Reported as:
Mean · mg/dL
Change From Baseline in LDL-C at Weeks 48 and 104
mg/dLStandard of CareEvolocumab + Standard of Care
Week 480.4 ± 43.9-68.8 ± 46.6
Week 104-66.4 ± 50.1-67.2 ± 46.6

Adverse events

Collected over 48 weeks in the SOC-controlled period and up to 2 years in the All-IP period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Year 1: Standard of Care5/1,227 (0.4%)104/1,227 (8.5%)334/1,227 (27.2%)
Year 1: Evolocumab + Standard of Care5/2,454 (0.2%)195/2,454 (7.9%)681/2,454 (27.8%)
Years 2-3: SOC / Evolocumab + SOC5/1,197 (0.4%)181/1,197 (15.1%)498/1,197 (41.6%)
Years 2-3: Evolocumab + SOC / Evolocumab + SOC16/2,391 (0.7%)344/2,391 (14.4%)928/2,391 (38.8%)
Years 2-3: Total21/3,588 (0.6%)525/3,588 (14.6%)1,426/3,588 (39.7%)
Most frequent serious events
Showing 10 of 497
Most frequent serious events
EventYear 1: Standard of CareYear 1: Evolocumab + Standard of CareYears 2-3: SOC / Evolocumab + SOCYears 2-3: Evolocumab + SOC / Evolocumab + SOCYears 2-3: Total
OsteoarthritisMusculoskeletal and connective tissue disorders5/122712/245422/119722/239144/3588
Angina pectorisCardiac disorders0/12277/245410/11978/239118/3588
Non-cardiac chest painGeneral disorders3/12274/245410/11978/239118/3588
Atrial fibrillationCardiac disorders3/12271/24547/11977/239114/3588
Acute myocardial infarctionCardiac disorders4/12278/24543/119712/239115/3588
PneumoniaInfections and infestations1/12270/24544/119712/239116/3588
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/12271/24546/11976/239112/3588
Angina unstableCardiac disorders6/12277/24544/119711/239115/3588
CholelithiasisHepatobiliary disorders0/12273/24545/11970/23915/3588
Aortic stenosisVascular disorders0/12271/24544/11970/23914/3588
Most frequent other events
Most frequent other events
EventYear 1: Standard of CareYear 1: Evolocumab + Standard of CareYears 2-3: SOC / Evolocumab + SOCYears 2-3: Evolocumab + SOC / Evolocumab + SOCYears 2-3: Total
NasopharyngitisInfections and infestations108/1227201/2454151/1197253/2391404/3588
Upper respiratory tract infectionInfections and infestations55/1227104/245499/1197178/2391277/3588
HypertensionVascular disorders56/122787/245478/1197180/2391258/3588
ArthralgiaMusculoskeletal and connective tissue disorders38/1227106/245480/1197162/2391242/3588
Back painMusculoskeletal and connective tissue disorders35/122783/245478/1197147/2391225/3588
BronchitisInfections and infestations43/122778/245470/1197132/2391202/3588
MyalgiaMusculoskeletal and connective tissue disorders43/122788/245461/119767/2391128/3588
InfluenzaInfections and infestations28/122766/245460/1197115/2391175/3588

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Standard of CareEvolocumab + Standard of CareTotal
Mean58.8 ± 10.758.6 ± 10.758.7 ± 10.7
Age, Customized
Age, Customized(Participants)Standard of CareEvolocumab + Standard of CareTotal
< 65 years82316652488
≥ 65 years4047891193
Sex: Female, Male
Sex: Female, Male(Participants)Standard of CareEvolocumab + Standard of CareTotal
Female56011761736
Male66712781945
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Standard of CareEvolocumab + Standard of CareTotal
Hispanic or Latino58109167
Not Hispanic or Latino116923453514
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Standard of CareEvolocumab + Standard of CareTotal
American Indian or Alaska Native257
Asian152288440
Black or African American4984133
Native Hawaiian or Other Pacific Islander224
White100320413044
Other163046
Mixed Race347
Region
Region(Participants)Standard of CareEvolocumab + Standard of CareTotal
North America51410011515
Europe50410181522
Asia Pacific209435644
Parent Study Baseline Low-density Lipoprotein Cholesterol (LDL-C) Concentration
Parent Study Baseline Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)Standard of CareEvolocumab + Standard of CareTotal
Mean125.8 ± 49.3127.4 ± 51.7126.9 ± 50.9
08

Study locations

363 sites
  • Research Site
    Birmingham, Alabama 35216, United States
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Phoenix, Arizona 85020, United States
  • Research Site
    Tucson, Arizona 85712, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Carmichael, California 95608, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Huntington Beach, California 92648, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Santa Ana, California 92705, United States
  • Research Site
    Santa Rosa, California 95405, United States
  • Research Site
    Spring Valley, California 91978, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Torrance, California 90509, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Melbourne, Florida 32901, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Ponte Vedra, Florida 32081, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Sanford, Florida 32771, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Atlanta, Georgia 30338, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Chicago, Illinois 60654, United States
  • Research Site
    Sterling, Illinois 61081, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Lexington, Kentucky 40504, United States
  • Research Site
    Louisville, Kentucky 40213, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Portland, Maine 04101, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Columbia, Maryland 21045, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Ayer, Massachusetts 01432, United States
  • Research Site
    Quincy, Massachusetts 02169, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Olive Branch, Mississippi 38654, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Endwell, New York 13760, United States
  • Research Site
    Manlius, New York 13104, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    Williamsville, New York 14221, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Akron, Ohio 44311, United States
  • Research Site
    Cadiz, Ohio 43907, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Cincinnati, Ohio 45236, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Dayton, Ohio 45414, United States
  • Research Site
    Mansfield, Ohio 44906, United States
  • Research Site
    Marion, Ohio 43302, United States
  • Research Site
    Sandusky, Ohio 44870, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Hillsboro, Oregon 97123, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Lansdale, Pennsylvania 19446, United States
  • Research Site
    Pittsburgh, Pennsylvania 15216, United States
  • Research Site
    York, Pennsylvania 17405, United States
  • Research Site
    Anderson, South Carolina 29621, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77074, United States

Showing the first 100 of 363 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31. PubMed 28844508 ↗
  • Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1448-1457. doi: 10.1016/j.jacl.2017.09.003. Epub 2017 Sep 22. PubMed 29066265 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
  • Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. PubMed 25773607 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in May 2018, 61 months.

Results were first posted in Jun 2019, 1 year after primary completion.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 61 months is above that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2013
First posted
May 16, 2013
StartActual
Apr 23, 2013
Primary completionActual
May 31, 2018
CompletionActual
May 31, 2018
Results first posted
Jun 11, 2019
Last update
Jun 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01854918
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 16, 2013
Start date
Apr 23, 2013
Primary completion
May 31, 2018
Completion
May 31, 2018
Results posted
Jun 11, 2019
Last update
Jun 11, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion